Ascendis Pharma A/S
ASND News Today: Stay Updated with the Latest Ascendis Pharma A/S News in Real Time
Find ASND news now at Meyka AI. Stay informed with the latest Ascendis Pharma A/S stocks updates, including price news, market analysis, and expert insights.
IGEA Pharma N.V. (IGPH.SW) Plunges 25% on Intraday Selling Pressure
IGPH.SW stock drops 25% intraday to CHF0.0015. Healthcare diagnostics firm faces heavy trading volume on SIX exchange.
SOLARA PHARMA (SOLR) Surges 14% on ₹9.6 Cr Q4 Profit; Revenue Soars 42% YoY
Solara Active Pharma Sciences reported a sharp earnings turnaround in Q4 FY26 as the company posted a net profit of ₹9.6 crore against a loss of nearly ₹142 crore in the year-ago quarter. The strong recovery immediately lifted investor sentiment, pushing SOLARA PHARMA shares up nearly 14 percent intraday toward the ₹700 level. Revenue from…
Open Orphan Plc (ORPH.IR) Holds Steady at €0.14 on EURONEXT
ORPH.IR stock trades flat at €0.14 on EURONEXT. Biotech firm specializes in human challenge trials and infectious disease research.
Addex Therapeutics (ADXN.SW) Jumps 6.7% as CNS Drug Pipeline Advances
ADXN.SW stock surges 6.7% to CHF 0.048 on SIX. Addex Therapeutics advances CNS drug programs including Dipraglurant and ADX71149.
IPSEY: Deutsche Bank Maintains Buy Rating, May 2026
Deutsche Bank maintains Buy rating on Ipsen (IPSEY), raising price target to EUR 183 from EUR 170 on May 14, 2026.
DNPUF Sumitomo Pharma Earnings Beat: Strong Revenue Surge
Sumitomo Pharma (DNPUF) beats EPS by 86.61% and revenue by 6.04% on May 13, 2026. Stock up 1.90% with $664.74M revenue.
Lansen Pharmaceutical Holdings Surges 40.94% on Strong Trading Volume
0503.HK stock jumps 40.94% to HK$1.79 with 13.96M shares traded. Lansen Pharmaceutical Holdings shows strong pre-market momentum on HKSE.
GBF.F Bilfinger SE Earnings Miss: EPS Falls Short
Bilfinger SE missed EPS estimates at $1.04 vs $1.06 expected, but matched $1.31B revenue. Stock fell 9% post-earnings.
Innate Pharma Surges 30% on Q1 Earnings Beat and Pipeline Progress
IPH.PA stock jumps 30% after Q1 2026 earnings announcement. Biotech firm advances clinical trials for oncology and immune therapies on EURONEXT.